Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop (iDCL) Trial.
Laya EkhlaspourDan RaghinaruGregory P ForlenzaElvira IsganaitisYogish C KudvaDavid W LamCamilla LevisterGrenye O'MalleyMei Mei ChurchJohn W LumBruce A BuckinghamSue A BrownPublished in: Journal of diabetes science and technology (2022)
There was a consistent benefit in patients with T1D when using CLC, regardless of baseline insulin delivery modality or CGM use. These data suggest that this CLC system can be considered across a wide range of patients.